All news

Russian pharmaceutical companies suspend production of coronavirus vaccines

As of today, more than 20 million vaccine doses with a finite shelf life are stored at the warehouse, the press service of Biocad said

MOSCOW, May 20. /TASS/. Several Russian pharmaceutical companies told TASS they have suspended production of the coronavirus vaccines due to the absence of orders.

"No orders for the production of the vaccine have come in 2022. As of today, more than 20 million vaccine doses with a finite shelf life are stored at the warehouse. That is why the vaccine production has been suspended," the press service of Biocad, a biopharmaceutical company manufacturing the Sputnik V coronavirus vaccine, said.

Another pharmaceutical company, Geropharm, also said it has received no orders for the production of the EpiVacCorona vaccine. It recalled that in 2021 orders had come from the Russian health ministry and the National Immunobiological Company, which had been completed in full.

No orders for the Sputnik V production have been received in 2022 by Binnopharm Group either. Its Director General Rustem Muratov said earlier that the country has enough vaccines.

Maxim Stetsyuk, Nanolec first deputy director general, has also said that his company has received no orders for the production of the CoviVac coronavirus vaccine from the Russian health ministry since December 2021. According to Stetsyuk, the company has manufactured around 500,000 vaccine doses and some 2.5 million doses more have been manufactured by the Chumakov Center.